Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.
"These results increase the...
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
A recent small study published in Nature’s Translational Psychiatry journal observed a change in the brain networking and behavior of boys receiving a video game-based treatment for ADHD.
Conducted in Singapore, the study was conducted as part of a larger controlled investigation of boys with ADHD. It compared an intervention group of 18 participants (mean age 9 years) to a control arm of 11...
Digital medicine company Akili Interactive Labs announced an $11.9 million expansion of its recent Series B funding, adding new investors into the round and bringing the series total to $42.4 million.
The Dutch subsidiary of Merck Ventures, known as M Ventures in the US and Canada, and the venture arm of Amgen joined existing investors, which include Pfizer and Shire Pharmaceuticals. This means...
Akili Interactive Labs will soon launch a clinical trial, called STARS-ADHD, that will evaluate the efficacy of its video game intervention for children with ADHD. The company plans to enroll a minimum of 300 children aged 8 to 12 years for its double-blind, randomized, controlled trial.
“Project: EVO has shown early promise to help improve attention and neurocognition in cognitive disorders like...
